

Megan Cully

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9443995/publications.pdf>

Version: 2024-02-01

113
papers

2,924
citations

687220

13
h-index

168321

53
g-index

119
all docs

119
docs citations

119
times ranked

5827
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiviral therapy targets latent HSV infections. Nature Reviews Drug Discovery, 2021, 20, 586-586.	21.5	1
2	Broadly neutralizing anti-coronavirus antibodies. Nature Reviews Drug Discovery, 2021, 20, 665-665.	21.5	2
3	T cell-regulating therapies for autoimmune diseases take FDA rejection in stride. Nature Reviews Drug Discovery, 2021, 20, 655-657.	21.5	4
4	Mopping up a molecule for breast cancer survival. Nature Reviews Drug Discovery, 2018, 17, 316-316.	21.5	0
5	Inflammasome protein seeds plaques in Alzheimer disease. Nature Reviews Drug Discovery, 2018, 17, 96-96.	21.5	2
6	Strategies for mature T cell cancers. Nature Reviews Cancer, 2018, 18, 3-3.	12.8	1
7	Tipping the splicing balance to kill cancer cells. Nature Reviews Drug Discovery, 2018, 17, 239-239.	21.5	1
8	Tipping the splicing balance to kill cancer cells. Nature Reviews Cancer, 2018, 18, 209-209.	12.8	2
9	Strategies for mature T cell cancers. Nature Reviews Drug Discovery, 2018, 17, 15-15.	21.5	2
10	Ropin' in ALS. Nature Reviews Drug Discovery, 2018, 17, 705-705.	21.5	0
11	Personalized cancer vaccines hit the spot. Nature Reviews Drug Discovery, 2018, 17, 393-393.	21.5	4
12	IDO inhibitors could change tack to treat metabolic disorders. Nature Reviews Drug Discovery, 2018, 17, 544-544.	21.5	5
13	Roche taps potential antibiotics mine with Warp Drive Bio. Nature Reviews Drug Discovery, 2018, 17, 9-9.	21.5	4
14	Tumour vessel normalization takes centre stage. Nature Reviews Drug Discovery, 2017, 16, 87-87.	21.5	30
15	MST1R inhibitor prevents bone osteolysis. Nature Reviews Drug Discovery, 2017, 16, 165-165.	21.5	3
16	Belt and braces for BCR-ABL. Nature Reviews Drug Discovery, 2017, 16, 313-313.	21.5	1
17	DAMPening damage after stroke. Nature Reviews Drug Discovery, 2017, 16, 385-385.	21.5	1
18	Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition. Nature Reviews Drug Discovery, 2017, 16, 377-377.	21.5	9

#	ARTICLE	IF	CITATIONS
19	Reinvigorating exhausted T cells in hepatitis B infection. Nature Reviews Immunology, 2017, 17, 218-218.	10.6	0
20	Reinvigorating exhausted T cells in hepatitis B infection. Nature Reviews Drug Discovery, 2017, 16, 240-240.	21.5	4
21	Cutting the antioxidant supply chain. Nature Reviews Drug Discovery, 2017, 16, 15-15.	21.5	3
22	Gut feeling on bacterial GPCR agonists. Nature Reviews Drug Discovery, 2017, 16, 754-754.	21.5	3
23	LKB1 helps Treg cells battle exhaustion. Nature Reviews Immunology, 2017, 17, 593-593.	10.6	1
24	An IL-9 solution to inflammation resolution. Nature Reviews Drug Discovery, 2017, 16, 601-601.	21.5	4
25	LKB1 helps Treg cells battle exhaustion. Nature Reviews Drug Discovery, 2017, 16, 680-680.	21.5	0
26	FGF19 reduces muscle wasting. Nature Reviews Drug Discovery, 2017, 16, 528-529.	21.5	0
27	Bispecific antibody directs T cells to solid tumours. Nature Reviews Drug Discovery, 2017, 16, 827-827.	21.5	5
28	BET inhibitor attenuates heart failure. Nature Reviews Drug Discovery, 2017, 16, 453-453.	21.5	9
29	Ximelagatran sets the stage for NOACs. Nature Reviews Cardiology, 2017, , .	6.1	7
30	Putting on the brakes: NOAC antidotes. Nature Reviews Cardiology, 2017, , .	6.1	2
31	Immunotoxins till the soil for stem cell transplantation. Nature Reviews Drug Discovery, 2016, 15, 454-455.	21.5	2
32	Laying the groundwork for remyelination. Nature Reviews Drug Discovery, 2016, 15, 384-384.	21.5	0
33	CXCR7 activation overrides lung fibrosis. Nature Reviews Drug Discovery, 2016, 15, 160-160.	21.5	3
34	Therapeutic post-infection options for Ebola virus treatment set to broaden. Nature Reviews Drug Discovery, 2016, 15, 307-307.	21.5	0
35	New tricks to treat Ebola. Nature Reviews Drug Discovery, 2016, 15, 675-675.	21.5	2
36	Anti-CD1a antibody reduces inflammation in psoriasis. Nature Reviews Drug Discovery, 2016, 15, 678-678.	21.5	4

#	ARTICLE	IF	CITATIONS
37	Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugai. Nature Reviews Drug Discovery, 2016, 15, 597-597.	21.5	0
38	Nosing around for new antibiotics. Nature Reviews Drug Discovery, 2016, 15, 604-604.	21.5	14
39	Exploiting a weakness in colorectal cancers. Nature Reviews Drug Discovery, 2016, 15, 820-821.	21.5	2
40	Winning at hide-and-seek with latent HIV reservoirs. Nature Reviews Drug Discovery, 2016, 15, 532-532.	21.5	3
41	Merck bets on purine receptor revival. Nature Reviews Drug Discovery, 2016, 15, 525-525.	21.5	1
42	Putting the brakes on preterm labour. Nature Reviews Drug Discovery, 2016, 15, 86-86.	21.5	0
43	Preventative treatment for infantile epilepsy. Nature Reviews Drug Discovery, 2016, 15, 17-17.	21.5	0
44	Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy. Nature Reviews Drug Discovery, 2015, 14, 374-375.	21.5	16
45	Repurposing for remyelination. Nature Reviews Drug Discovery, 2015, 14, 383-383.	21.5	4
46	Celgene bets big on Scripps-originated autoimmunity candidate. Nature Reviews Drug Discovery, 2015, 14, 595-595.	21.5	0
47	FXR and JAK step up to BAT. Nature Reviews Drug Discovery, 2015, 14, 91-91.	21.5	7
48	Genetic information adds supporting weight. Nature Reviews Drug Discovery, 2015, 14, 525-525.	21.5	7
49	Tuning kinase inhibitor residence time. Nature Reviews Drug Discovery, 2015, 14, 457-457.	21.5	4
50	MYDGF promotes heart repair after myocardial infarction. Nature Reviews Drug Discovery, 2015, 14, 164-165.	21.5	6
51	Advancing precision medicine in silico. Nature Reviews Drug Discovery, 2015, 14, 311-311.	21.5	8
52	Multikinase-targeting therapy finds potential niche in thyroid cancer. Nature Reviews Drug Discovery, 2015, 14, 229-229.	21.5	6
53	Parasite-targeting compound sets identified and ready to go. Nature Reviews Drug Discovery, 2015, 14, 238-238.	21.5	1
54	Hydrogel drug delivery for inflammatory bowel disease. Nature Reviews Drug Discovery, 2015, 14, 678-679.	21.5	16

#	ARTICLE	IF	CITATIONS
55	Telomerase inhibitor shows promise in myeloproliferative disorders. Nature Reviews Drug Discovery, 2015, 14, 741-741.	21.5	5
56	A one-two punch for KRAS-driven cancer. Nature Reviews Drug Discovery, 2015, 14, 600-600.	21.5	0
57	Long live the peptides. Nature Reviews Drug Discovery, 2015, 14, 750-750.	21.5	3
58	GRBbing longevity with both insulin signalling arms. Nature Reviews Drug Discovery, 2015, 14, 600-601.	21.5	0
59	Xenograft encyclopaedia identifies drug combination opportunities. Nature Reviews Drug Discovery, 2015, 14, 819-819.	21.5	0
60	Public health: The politics of antibiotics. Nature, 2014, 509, S16-S17.	13.7	103
61	Timing is everything for Nogo-specific antibodies. Nature Reviews Drug Discovery, 2014, 13, 575-575.	21.5	0
62	Medical adherence after discharge. Nature Reviews Cardiology, 2014, 11, 6-6.	6.1	0
63	Redesigned antibiotic combats drug-resistant tuberculosis. Nature Reviews Drug Discovery, 2014, 13, 257-257.	21.5	6
64	'Fish'ing for regulators of inflammation. Nature Reviews Drug Discovery, 2014, 13, 335-335.	21.5	0
65	Adenosine protects from diet-induced obesity. Nature Reviews Drug Discovery, 2014, 13, 886-887.	21.5	4
66	IL-25 blockade could reduce virus-associated asthma attacks. Nature Reviews Drug Discovery, 2014, 13, 811-811.	21.5	5
67	Self-inactivating gene-therapy vector alleviates safety concerns. Nature Reviews Drug Discovery, 2014, 13, 879-879.	21.5	3
68	Lilly buys back into the BACE race for Alzheimer's disease. Nature Reviews Drug Discovery, 2014, 13, 804-804.	21.5	5
69	Turning glioblastoma cells vacuous. Nature Reviews Drug Discovery, 2014, 13, 417-417.	21.5	0
70	Next-generation antimalarial from phenotypic screen shows clinical promise. Nature Reviews Drug Discovery, 2014, 13, 717-717.	21.5	8
71	Atopic dermatitis therapy breakthrough on the horizon?. Nature Reviews Drug Discovery, 2014, 13, 645-645.	21.5	2
72	Beefing up the right splice variant to treat spinal muscular atrophy. Nature Reviews Drug Discovery, 2014, 13, 725-725.	21.5	1

#	ARTICLE	IF	CITATIONS
73	Pillars of remyelination. Nature Reviews Drug Discovery, 2014, 13, 651-651.	21.5	2
74	Drug development: Illuminated targets. Nature, 2014, 511, S12-S13.	13.7	6
75	Novartis eyes vision-enhancing therapy for macular degeneration. Nature Reviews Drug Discovery, 2014, 13, 487-487.	21.5	0
76	Using firefly genes to make household plants glow/Learn how to make your own glowing plant. New Scientist, 2014, 222, 27.	0.0	0
77	Dual RAAS blocker trial stopped prematurely. Nature Reviews Nephrology, 2013, 9, 3-3.	4.1	2
78	Frequent somatic symptoms in CHD. Nature Reviews Cardiology, 2013, 10, 431-431.	6.1	0
79	Drug-eluting balloons for the treatment of critical limb ischaemia. Nature Reviews Cardiology, 2013, 10, 430-430.	6.1	0
80	Remnant cholesterol is associated with ischaemic heart disease. Nature Reviews Cardiology, 2013, 10, 119-119.	6.1	2
81	Adhesive-hydrogel composite developed to repair damaged cartilage. Nature Reviews Rheumatology, 2013, 9, 135-135.	3.5	10
82	Noncardiac surgery and stents. Nature Reviews Cardiology, 2013, 10, 681-681.	6.1	0
83	Treating restenosis after drug-eluting stent implantation. Nature Reviews Cardiology, 2013, 10, 62-62.	6.1	1
84	Long-term dabigatran therapy reduces the risk of recurrent venous thromboembolism. Nature Reviews Cardiology, 2013, 10, 240-240.	6.1	0
85	Long-term follow-up from PROTECT AF trial reported. Nature Reviews Cardiology, 2013, 10, 120-120.	6.1	1
86	Ranolazine decreases angina. Nature Reviews Cardiology, 2013, 10, 239-239.	6.1	0
87	n-3 fatty acids provide little benefit. Nature Reviews Cardiology, 2013, 10, 365-365.	6.1	0
88	Tardy but intactâ€”publication of REVIVE trial results welcomed. Nature Reviews Cardiology, 2013, 10, 297-297.	6.1	0
89	Data-driven criteria for defining SpA using MRI. Nature Reviews Rheumatology, 2013, 9, 65-65.	3.5	1
90	Dual RAAS blocker trial stopped prematurely. Nature Reviews Cardiology, 2013, 10, 5-5.	6.1	0

#	ARTICLE	IF	CITATIONS
91	Multivitamins do not reduce the risk of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 7-7.	6.1	0
92	The benefits and challenges of smoking cessation. <i>Nature Reviews Cardiology</i> , 2013, 10, 117-117.	6.1	5
93	Mitral valve repair with CABG surgery. <i>Nature Reviews Cardiology</i> , 2013, 10, 6-6.	6.1	0
94	The dangers of digoxin in AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 61-61.	6.1	0
95	Immunosuppressive cells identified in mouse models of SLE. <i>Nature Reviews Rheumatology</i> , 2013, 9, 445-445.	3.5	2
96	Mohawk is downregulated in ACLs from knees with OA. <i>Nature Reviews Rheumatology</i> , 2013, 9, 384-384.	3.5	0
97	Drug development: Chemical brace. <i>Nature</i> , 2013, 503, S10-S12.	13.7	1
98	Altered Wnt signalling in intervertebral disc degeneration. <i>Nature Reviews Rheumatology</i> , 2013, 9, 136-136.	3.5	11
99	Sorting out and comparing stents. <i>Nature Reviews Cardiology</i> , 2013, 10, 181-181.	6.1	0
100	RNAi targeting PCSK9 decreases lipid levels in a human trial. <i>Nature Reviews Cardiology</i> , 2013, 10, 682-682.	6.1	4
101	Catheter ablation is better than drugs to treat persistent AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 680-680.	6.1	0
102	Interstitial lung disease treated with mycophenolate mofetil. <i>Nature Reviews Rheumatology</i> , 2013, 9, 198-198.	3.5	0
103	Proportion of asymptomatic AF increases after catheter ablation. <i>Nature Reviews Cardiology</i> , 2013, 10, 119-119.	6.1	1
104	Increased number of complications with dual-chamber ICDs. <i>Nature Reviews Cardiology</i> , 2013, 10, 364-364.	6.1	0
105	Assessing Cell Size and Cell Cycle Regulation in Cells with Altered TOR Activity. <i>Methods in Molecular Biology</i> , 2012, 821, 227-237.	0.4	1
106	A Role for p38 Stress-Activated Protein Kinase in Regulation of Cell Growth via TORC1. <i>Molecular and Cellular Biology</i> , 2010, 30, 481-495.	1.1	79
107	Translational responses to growth factors and stress. <i>Biochemical Society Transactions</i> , 2009, 37, 284-288.	1.6	28
108	SnapShot: Ras Signaling. <i>Cell</i> , 2008, 133, 1292-1292.e1.	13.5	71

#	ARTICLE	IF	CITATIONS
109	SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth. <i>Cell Metabolism</i> , 2008, 8, 224-236.	7.2	1,103
110	Insulin delays the progression of <i>Drosophila</i> cells through G2/M by activating the dTOR/dRaptor complex. <i>EMBO Journal</i> , 2007, 26, 371-379.	3.5	40
111	Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. <i>Nature Reviews Cancer</i> , 2006, 6, 184-192.	12.8	1,119
112	Transforming Acidic Coiled Coil 1 Promotes Transformation and Mammary Tumorigenesis. <i>Cancer Research</i> , 2005, 65, 10363-10370.	0.4	57
113	grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15358-15363.	3.3	16